Alex Sánchez
University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alex Sánchez.
Brain | 2009
Manuel Comabella; Jan D. Lünemann; Jordi Río; Alex Sánchez; C. López; Eva Julià; M. Fernández; L. Nonell; M. Camiña-Tato; Florian Deisenhammer; E. Caballero; M. T. Tortola; Marco Prinz; Xavier Montalban; Roland Martin
The effect of interferon-beta in multiple sclerosis is modest and many patients do not respond to treatment. To date, no single biomarker reliably correlates with responsiveness to interferon-beta in multiple sclerosis. In the present study, genome-wide expression profiling was performed in peripheral blood mononuclear cells from 47 multiple sclerosis patients treated with interferon-beta for a minimum of 2 years and classified as responders and non-responders based on clinical criteria. A validation cohort of 30 multiple sclerosis patients was included in the study to replicate gene-expression findings. Before treatment, interferon-beta responders and non-responders were characterized by differential expression of type I interferon-induced genes with overexpression of the type interferon-induced genes in non-responders. Upon treatment the expression of these genes remained unaltered in non-responders, but was strongly upregulated in responders. Functional experiments showed a selective increase in phosphorylated STAT1 levels and interferon receptor 1 expression in monocytes of non-responders at baseline. When dissecting this type I interferon signature further, interferon-beta non-responders were characterized by increased monocyte type I interferon secretion upon innate immune stimuli via toll-like receptor 4, by increased endogenous production of type I interferon, and by an elevated activation status of myeloid dendritic cells. These findings indicate that perturbations of the type I interferon signalling pathway in monocytes are related to lack of response to interferon-beta, and type I interferon-regulated genes may be used as response markers in interferon-beta treatment.
Brain | 2015
Ester Cantó; Mar Tintoré; Luisa M. Villar; Carme Costa; Ramil Nurtdinov; José C. Álvarez-Cermeño; Georgina Arrambide; Ferran Reverter; Florian Deisenhammer; Harald Hegen; Mohsen Khademi; Tomas Olsson; Hayrettin Tumani; Eulalia Rodríguez-Martín; Fredrik Piehl; Ales Bartos; Denisa Zimova; Jens Kuhle; Ludwig Kappos; Garcia-Merino Ja; Antonio J. Sánchez; Albert Saiz; Yolanda Blanco; Rogier Q. Hintzen; Naghmeh Jafari; David Brassat; Florian Lauda; Romy Roesler; Konrad Rejdak; Ewa Papuć
Chitinase 3-like 1 (CHI3L1) has been proposed as a biomarker associated with the conversion to clinically definite multiple sclerosis in patients with clinically isolated syndromes, based on the finding of increased cerebrospinal fluid CHI3L1 levels in clinically isolated syndrome patients who later converted to multiple sclerosis compared to those who remained as clinically isolated syndrome. Here, we aimed to validate CHI3L1 as a prognostic biomarker in a large cohort of patients with clinically isolated syndrome. This is a longitudinal cohort study of clinically isolated syndrome patients with clinical, magnetic resonance imaging, and cerebrospinal fluid data prospectively acquired. A total of 813 cerebrospinal fluid samples from patients with clinically isolated syndrome were recruited from 15 European multiple sclerosis centres. Cerebrospinal fluid CHI3L1 levels were measured by enzyme-linked immunosorbent assay. Multivariable Cox regression models were used to investigate the association between cerebrospinal fluid CHI3L1 levels and time to conversion to multiple sclerosis and time to reach Expanded Disability Status Scale 3.0. CHI3L1 levels were higher in patients who converted to clinically definite multiple sclerosis compared to patients who continued as clinically isolated syndrome (P = 8.1 × 10(-11)). In the Cox regression analysis, CHI3L1 levels were a risk factor for conversion to multiple sclerosis (hazard ratio = 1.7; P = 1.1 × 10(-5) using Poser criteria; hazard ratio = 1.6; P = 3.7 × 10(-6) for McDonald criteria) independent of other covariates such as brain magnetic resonance imaging abnormalities and presence of cerebrospinal fluid oligoclonal bands, and were the only significant independent risk factor associated with the development of disability (hazard ratio = 3.8; P = 2.5 × 10(-8)). High CHI3L1 levels were associated with shorter time to multiple sclerosis (P = 3.2 × 10(-9) using Poser criteria; P = 5.6 × 10(-11) for McDonald criteria) and more rapid development of disability (P = 1.8 × 10(-10)). These findings validate cerebrospinal fluid CHI3L1 as a biomarker associated with the conversion to multiple sclerosis and development of disability and reinforce the prognostic role of CHI3L1 in patients with clinically isolated syndrome. We propose that determining cerebrospinal fluid chitinase 3-like 1 levels at the time of a clinically isolated syndrome event will help identify those patients with worse disease prognosis.
PLOS ONE | 2012
Francisco Rodriguez-Frias; D. Tabernero; Josep Quer; Juan Ignacio Esteban; Israel Ortega; Esteban Domingo; María Angustias Cubero; Sílvia Camós; Carles Ferrer-Costa; Alex Sánchez; Rosendo Jardi; Melanie Schaper; Maria Homs; Damir Garcia-Cehic; J. Guardia; Rafael Esteban; Maria Buti
Background Selection of amino acid substitutions associated with resistance to nucleos(t)ide-analog (NA) therapy in the hepatitis B virus (HBV) reverse transcriptase (RT) and their combination in a single viral genome complicates treatment of chronic HBV infection and may affect the overlapping surface coding region. In this study, the variability of an overlapping polymerase-surface region, critical for NA resistance, is investigated before treatment and under antiviral therapy, with assessment of NA-resistant amino acid changes simultaneously occurring in the same genome (linkage analysis) and their influence on the surface coding region. Methodology/Principal Findings Serum samples obtained from chronic HBV-infected patients at pre-treatment and during sequential NA treatment with lamivudine, adefovir, and entecavir were analyzed by ultra-deep pyrosequencing (UDPS) using the GS-FLX platform (454 Life Sciences-Roche). The pre-treatment HBV quasispecies was not enriched with NA-resistant substitutions. The frequencies of this type of substitutions at pre-treatment did not predict the frequencies observed during lamivudine treatment. On linkage analysis of the RT region studied, NA-resistant HBV variants (except for rtA181T) were present in combinations of amino acid substitutions that increased in complexity after viral breakthrough to entecavir, at which time the combined variant rtL180M-S202G-M204V-V207I predominated. In the overlapping surface region, NA-resistant substitutions caused selection of stop codons in a significant percentage of sequences both at pre-treatment and during sequential treatment; the rtA181T substitution, related to sW172stop, predominated during treatment with lamivudine and adefovir. A highly conserved RT residue (rtL155), even more conserved than the essential residues in the RT catalytic motif YMDD, was identified in all samples. Conclusions UDPS methodology enabled quantification of HBV quasispecies variants, even those harboring complex combinations of amino acid changes. The high percentage of potentially defective genomes, especially in the surface region, suggests effective trans-complementation of these variants.
The Prostate | 2010
Marina Rigau; Juan Morote; Maria Carmen Mir; Carlos Ballesteros; Israel Ortega; Alex Sánchez; Eva Colas; Marta Garcia; Anna Ruiz; Miguel Abal; Jacques Planas; Jaume Reventós; Andreas Doll
Several studies have demonstrated the usefulness of monitoring an RNA transcript in urine, such as PCA3, for prostate cancer (PCa) diagnosis. PCa screening would benefit from additional biomarkers of higher specificity and could be used in conjunction with prostate‐specific antigen (PSA) testing, in order to better determine biopsy candidates.
Acta Diabetologica | 2013
Matteo Serino; José Manuel Fernández-Real; Eduardo García Fuentes; Maribel Queipo-Ortuño; José María Moreno-Navarrete; Alex Sánchez; Rémy Burcelin; Francisco J. Tinahones
The role of the gut microbiota in the induction of metabolic diseases has now been increasingly recognized worldwide. Indeed, a specific gut microbiota has been shown to characterize lean versus obese phenotypes both in humans and mice. We have also recently demonstrated that a precise gut microbiota is associated with the host’s responsiveness to a high-fat diet. Therefore, we hypothesized that insulin resistance in humans could also be linked to a specific gut microbiota. To this aim, microbial DNA and RNA were extracted from the appendix contents of insulin-resistant versus insulin-sensitive obese subjects, matched for body mass index and age, and analyzed by DNA- and RNA-DGGE. Microbial DNA analysis showed that the patients fully segregated according to their degree of insulin action. Conversely, microbial RNA investigation showed that some degree of homology still existed between insulin-sensitive and insulin-resistant patients. Quantitative trait analysis, ordinary least squares regression, principal components regression, partial least squares, canonical correlation analysis, and canonical correspondence analysis also showed a net separation of the two phenotypes analyzed. We conclude that a specific gut microbial profile is associated with insulin action in humans.
The Prostate | 2011
Marina Rigau; Israel Ortega; Maria Carmen Mir; Carlos Ballesteros; Marta Garcia; Marta Llauradó; Eva Colas; Nuria Pedrola; Melania Montes; Tamara Sequeiros; Tugçe Ertekin; Blanca Majem; Jacques Planas; Anna Ruiz; Miguel Abal; Alex Sánchez; Juan Morote; Jaume Reventós; Andreas Doll
Several studies have demonstrated the usefulness of monitoring an RNA transcript, such as PCA3, in post‐prostate massage (PM) urine for increasing the specificity of prostate‐specific antigen (PSA) in the detection of prostate cancer (PCa). However, a single marker may not necessarily reflect the multifactorial nature of PCa.
Revista De Historia Economica | 2000
Alex Sánchez
espanolEl objetivo de este trabajo es analizar los inicios del sistema fabril en la industria algodonera catalana, mostrando como fue justamente durante el periodo que abarca la crisis del Antiguo Regimen cuando se pusieron los fundamentos de la industrializacion catalana. En la primera parte se estudian las condiciones que permitieron la aparicion de las primeras hilaturas mecanicas en los anos del cambio de siglo. En la segunda se aborda la continuidad del proceso de modernizacion industrial tras la Guerra de la Independencia. Se intenta mostrar como la respuesta empresarial a la crisis provocada por la perdida de las colonias americanas y la quiebra de la hacienda publica consistio basicamente en la apuesta por el cambio tecnico y organizativo EnglishThis paper is aimed at analysing the origins of the factory system in the Catalan cotton industry. It concludes that the Catalan industrialisation process can be considered to have been founded during the crisis of the Spanish Ancient Regime. In order to show this, two different pieces of information are presented. Firstly, the appearance of the first mechanical spinning mills by the end of the 18th century, as well as the conditions that allowed it, is studied. Secondly, the subsequent modernisation of the sector after the Spanish War of Independence is analysed. We try to show that, after the crisis brought about by the loss of the Empire and the bankruptcy of the Treasury, the response of the sector mainly consisted of intensifying technical and organisational change and defending commercial prohibicionism.
Multiple Sclerosis Journal | 2012
Ester Cantó; Ferran Reverter; C Morcillo-Suárez; Fuencisla Matesanz; Oscar Fernández; Guillermo Izquierdo; Koen Vandenbroeck; A. Rodríguez-Antigüedad; Elena Urcelay; Rafael Arroyo; David Otaegui; Javier Olascoaga; Albert Saiz; Arcadi Navarro; Alex Sánchez; C Domínguez; Ana Caminero; Alejandro Horga; Mar Tintoré; Xavier Montalban; Manuel Comabella
Background: Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis. Objective: The objective of this study was to investigate the role of plasma CHI3L1 in MS clinical course and disease activity and to evaluate the effect of interferon-beta (IFNβ) treatment on protein levels. Methods: Plasma CHI3L1 levels were determined by ELISA in 57 healthy controls (HC), 220 untreated MS patients [66 primary progressive MS patients (PPMS), 30 secondary progressive MS patients (SPMS), and 124 relapsing–remitting MS patients (RRMS), 94 during clinical remission and 30 during relapse], and 32 MS patients receiving IFNβ treatment. A polymorphism of the CHI3L1 gene, rs4950928, was genotyped in 3274 MS patients and 3483 HC. Results: Plasma CHI3L1 levels were significantly increased in patients with progressive forms of MS compared with RRMS patients and HC. CHI3L1 levels were similar between RRMS patients in relapse and remission. A trend towards decreased CHI3L1 levels was observed in IFNβ-treated patients. Allele C of rs4950928 was significantly associated with PPMS patients and with higher plasma CHI3L1 levels. Conclusions: These findings point to a role of CHI3L1 in patients with progressive forms of MS, particularly in those with PPMS.
PLOS ONE | 2015
Irma Pujol-Autonell; Arnau Serracant-Prat; Mary Cano-Sarabia; Rosa Maria Ampudia; Silvia Rodríguez-Fernández; Alex Sánchez; Cristina Izquierdo; Thomas Stratmann; Manuel Puig-Domingo; Daniel Maspoch; Joan Verdaguer; Marta Vives-Pi
Introduction The development of new therapies to induce self-tolerance has been an important medical health challenge in type 1 diabetes. An ideal immunotherapy should inhibit the autoimmune attack, avoid systemic side effects and allow β-cell regeneration. Based on the immunomodulatory effects of apoptosis, we hypothesized that apoptotic mimicry can help to restore tolerance lost in autoimmune diabetes. Objective To generate a synthetic antigen-specific immunotherapy based on apoptosis features to specifically reestablish tolerance to β-cells in type 1 diabetes. Methods A central event on the surface of apoptotic cells is the exposure of phosphatidylserine, which provides the main signal for efferocytosis. Therefore, phosphatidylserine-liposomes loaded with insulin peptides were generated to simulate apoptotic cells recognition by antigen presenting cells. The effect of antigen-specific phosphatidylserine-liposomes in the reestablishment of peripheral tolerance was assessed in NOD mice, the spontaneous model of autoimmune diabetes. MHC class II-peptide tetramers were used to analyze the T cell specific response after treatment with phosphatidylserine-liposomes loaded with peptides. Results We have shown that phosphatidylserine-liposomes loaded with insulin peptides induce tolerogenic dendritic cells and impair autoreactive T cell proliferation. When administered to NOD mice, liposome signal was detected in the pancreas and draining lymph nodes. This immunotherapy arrests the autoimmune aggression, reduces the severity of insulitis and prevents type 1 diabetes by apoptotic mimicry. MHC class II tetramer analysis showed that peptide-loaded phosphatidylserine-liposomes expand antigen-specific CD4+ T cells in vivo. The administration of phosphatidylserine-free liposomes emphasizes the importance of phosphatidylserine in the modulation of antigen-specific CD4+ T cell expansion. Conclusions We conclude that this innovative immunotherapy based on the use of liposomes constitutes a promising strategy for autoimmune diseases.
Cancer Research | 2014
Thaïs Cuadros; Enric Trilla; Eduard Sarró; Maya R. Vilà; Jordi Vilardell; Inés M. de Torres; Mayte Salcedo; Joan López-Hellin; Alex Sánchez; Santiago Ramón y Cajal; Emilio Itarte; Juan Morote; Anna Meseguer
Renal cell carcinoma (RCC), the third most prevalent urological cancer, claims more than 100,000 lives/year worldwide. The clear cell variant (ccRCC) is the most common and aggressive subtype of this disease. While commonly asymptomatic, more than 30% of ccRCC are diagnosed when already metastatic, resulting in a 95% mortality rate. Notably, nearly one-third of organ-confined cancers treated by nephrectomy develop metastasis during follow-up care. At present, diagnostic and prognostic biomarkers to screen, diagnose, and monitor renal cancers are clearly needed. The gene encoding the cell surface molecule HAVCR1/KIM-1 is a suggested susceptibility gene for ccRCC and ectodomain shedding of this molecule may be a predictive biomarker of tumor progression. Microarray analysis of 769-P ccRCC-derived cells where HAVCR/KIM-1 levels have been upregulated or silenced revealed relevant HAVCR/KIM-1-related targets, some of which were further analyzed in a cohort of 98 ccRCC patients with 100 month follow-up. We found that HAVCR/KIM-1 activates the IL-6/STAT-3/HIF-1A axis in ccRCC-derived cell lines, which depends on HAVCR/KIM-1 shedding. Moreover, we found that pSTAT-3 S727 levels represented an independent prognostic factor for ccRCC patients. Our results suggest that HAVCR/KIM-1 upregulation in tumors might represent a novel mechanism to activate tumor growth and angiogenesis and that pSTAT-3 S727 is an independent prognostic factor for ccRCC.